Loading clinical trials...

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) | Clinical Trials | Clareo Health

TERMINATEDPhase 3

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

A Randomized, Double-blind, Placebo-controlled, Phase III, Multi-centre Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With IPSS Intermediate-1, Intermediate 2 and High-risk Myelodysplastic Syndromes (MDS) SUPPORT: A StUdy of eltromboPag in myelodysPlastic SyndrOmes Receiving azaciTidine

NCT02158936•Novartis Pharmaceuticals

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Thrombocytopaenia

Interventions

Eltrombopag

Azacitidine

+2 more

Locations

155

United States

Locations (155)

Novartis Investigative Site

Hartford, Connecticut, United States

Novartis Investigative Site

Atlanta, Georgia, United States

Novartis Investigative Site

Chicago, Illinois, United States

Novartis Investigative Site

Anderson, Indiana, United States

Novartis Investigative Site

Kansas City, Missouri, United States

Novartis Investigative Site

St Louis, Missouri, United States

Key Dates

Start Date

June 10, 2014

Primary Completion Date

April 30, 2016

Completion Date

April 30, 2016

Last Updated

December 12, 2017

Related Studies

Clinical Efficacy of Platelet Transfusion

NCT06805097

ThrombocytopaeniaHaematological Malignancies

COMPLETEDPhase 4

A Rollover Study to Provide Continued Treatment With Eltrombopag

NCT01957176

Thrombocytopaenia

Meta-analysis - Eltrombopag

NCT01235988

Thrombocytopaenia

WITHDRAWNPhase 4

Milk-only Lactation Study for Patients on Eltrombopag

NCT01055600

Thrombocytopaenia

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 12, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions